Journal club: the retatrutide phase 2 obesity paper

Journal club: the retatrutide phase 2 obesity paper — setting out what I have, and where I think it stops being reliable.

Collecting what is known about retatrutide phase 2 obesity paper in one place, because it is currently spread across a category, two tag pages and a thread that is hard to find.

This is a summary rather than new work, and I have attributed each part to where I found it.

Sessions run better when the paper is circulated with three specific questions attached. Open-ended reading produces an open-ended discussion.

Someone will know this better than I do and I hope they say so.

This is the answer, and the reason it is the answer is the more useful part.

On post #4 — agreed on the reasoning, with one qualification.

Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent.

Picking up post #4: that is the part I would want checked first.

Suggest the next paper at the end of the session rather than by message afterwards. The room has just worked out what it wants to know next.

SURMOUNT-1 (N Engl J Med 2022): Tirzepatide obesity trial. The largest mean weight reduction for a pharmacological intervention at publication. Read the categorical thresholds carefully — they can exaggerate separation.

Worth checking against a second source before it gets quoted onward.

STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially larger than anything previously achieved pharmacologically.

That is my reading. Someone else read the same page differently and was reasonable.

TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.

The right answer here may simply be that it has not been measured.

Appreciated. The plain phrasing does more work here than a longer post would.

Somebody should be asked to argue the paper's case even if nobody in the room believes it. Sessions where everyone agrees produce a summary nobody can use.

Worth one more sentence than it usually gets.

Quoting the sentence rather than paraphrasing it changes the discussion. Paraphrase is where a claim quietly becomes stronger than the paper made it.